2vci: Difference between revisions

Jump to navigation Jump to search
← Older edit
No edit summary
No edit summary
 
(11 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Image:2vci.jpg|left|200px]]
<!--
The line below this paragraph, containing "STRUCTURE_2vci", creates the "Structure Box" on the page.
You may change the PDB parameter (which sets the PDB file loaded into the applet)
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
or leave the SCENE parameter empty for the default display.
-->
{{STRUCTURE_2vci|  PDB=2vci  |  SCENE=  }}
'''4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER'''


==4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer==
<StructureSection load='2vci' size='340' side='right'caption='[[2vci]], [[Resolution|resolution]] 2.00&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[2vci]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VCI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2VCI FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2GJ:5-[2,4-DIHYDROXY-5-(1-METHYLETHYL)PHENYL]-N-ETHYL-4-[4-(MORPHOLIN-4-YLMETHYL)PHENYL]ISOXAZOLE-3-CARBOXAMIDE'>2GJ</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2vci FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vci OCA], [https://pdbe.org/2vci PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2vci RCSB], [https://www.ebi.ac.uk/pdbsum/2vci PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2vci ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/HS90A_HUMAN HS90A_HUMAN] Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.<ref>PMID:15937123</ref> <ref>PMID:11274138</ref>
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
Check<jmol>
  <jmolCheckbox>
    <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/vc/2vci_consurf.spt"</scriptWhenChecked>
    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
    <text>to colour the structure by Evolutionary Conservation</text>
  </jmolCheckbox>
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=2vci ConSurf].
<div style="clear:both"></div>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%.


==Overview==
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.,Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L J Med Chem. 2008 Jan 24;51(2):196-218. Epub 2007 Nov 20. PMID:18020435<ref>PMID:18020435</ref>
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%.


==About this Structure==
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
2VCI is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VCI OCA].
</div>
<div class="pdbe-citations 2vci" style="background-color:#fffaf0;"></div>


==Reference==
==See Also==
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer., Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L, J Med Chem. 2008 Jan 24;51(2):196-218. Epub 2007 Nov 20. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/18020435 18020435]
*[[Heat Shock Protein structures|Heat Shock Protein structures]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Large Structures]]
[[Category: Aherne, W.]]
[[Category: Aherne W]]
[[Category: Barril, X.]]
[[Category: Barril X]]
[[Category: Borgognoni, J.]]
[[Category: Borgognoni J]]
[[Category: Boxal, K.]]
[[Category: Boxal K]]
[[Category: Brough, P A.]]
[[Category: Brough PA]]
[[Category: Cansfield, J E.]]
[[Category: Cansfield JE]]
[[Category: Cheung, K M.]]
[[Category: Cheung KM]]
[[Category: Collins, I.]]
[[Category: Collins I]]
[[Category: Davies, N G.M.]]
[[Category: Davies NGM]]
[[Category: Drysdale, M J.]]
[[Category: Drysdale MJ]]
[[Category: Dymock, B.]]
[[Category: Dymock B]]
[[Category: Eccles, S A.]]
[[Category: Eccles SA]]
[[Category: Finch, H.]]
[[Category: Finch H]]
[[Category: Fink, A.]]
[[Category: Fink A]]
[[Category: Hayes, A.]]
[[Category: Hayes A]]
[[Category: Howes, R.]]
[[Category: Howes R]]
[[Category: Hubbard, R E.]]
[[Category: Hubbard RE]]
[[Category: James, K.]]
[[Category: James K]]
[[Category: Jordan, A M.]]
[[Category: Jordan AM]]
[[Category: Lockie, A.]]
[[Category: Lockie A]]
[[Category: Martins, V.]]
[[Category: Martins V]]
[[Category: Massey, A.]]
[[Category: Massey A]]
[[Category: Matthews, T P.]]
[[Category: Matthews TP]]
[[Category: Mcdonald, E.]]
[[Category: McDonald E]]
[[Category: Northfield, C J.]]
[[Category: Northfield CJ]]
[[Category: Pearl, L H.]]
[[Category: Pearl LH]]
[[Category: Prodromou, C.]]
[[Category: Prodromou C]]
[[Category: Ray, S.]]
[[Category: Ray S]]
[[Category: Raynaud, F I.]]
[[Category: Raynaud FI]]
[[Category: Roughley, S D.]]
[[Category: Roughley SD]]
[[Category: Sharp, S Y.]]
[[Category: Sharp SY]]
[[Category: Surgenor, A.]]
[[Category: Surgenor A]]
[[Category: Walmsley, D L.]]
[[Category: Walmsley DL]]
[[Category: Webb, P.]]
[[Category: Webb P]]
[[Category: Wood, M.]]
[[Category: Wood M]]
[[Category: Workman, P.]]
[[Category: Workman P]]
[[Category: Wright, L.]]
[[Category: Wright L]]
[[Category: Alternative splicing]]
[[Category: Atp-binding]]
[[Category: Chaperone]]
[[Category: Cytoplasm]]
[[Category: Nucleotide-binding]]
[[Category: Phosphorylation]]
[[Category: Stress response]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 18:35:33 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA
Retrieved from "https://proteopedia.openfox.io/w/2vci"